Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765179 dose-finding and expansion study in advanced solid cancers and first-line PD-L1-positive recurrent/metastatic HNSCC
jRCT2031210652Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of BI 765179 in Nonhematologic neoplasms and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicities during MTD evaluation period and 1 more. Started Jul 2022; status: active, not recruiting.
02
Drugs
BI 765179
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031210652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210652.